發(fā)布時(shí)間：2018-10-12 09:31

【摘要】：目的系統(tǒng)評價(jià)養(yǎng)血清腦顆粒治療中風(fēng)后抑郁的療效及安全性,為臨床藥物治療提供循證依據(jù)。方法利用計(jì)算機(jī)檢索CNKI、中國生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(CBM)、萬方數(shù)據(jù)庫、維普期刊數(shù)據(jù)庫(VIP)、Pub Med、Cochrane Library等數(shù)據(jù)庫,搜集養(yǎng)血清腦顆粒治療中風(fēng)后抑郁的隨機(jī)對照試驗(yàn),檢索時(shí)限為從建庫至2016年4月10日。指定2名評價(jià)員分別篩選文獻(xiàn)并對所納入研究進(jìn)行方法學(xué)質(zhì)量評價(jià),然后提取數(shù)據(jù)并利用RevMan5.3軟件完成Meta分析。結(jié)果最終10項(xiàng)隨機(jī)對照試驗(yàn)納入本Meta分析,包含1035例患者。養(yǎng)血清腦顆粒聯(lián)合抗抑郁藥治療中風(fēng)后抑郁≥28 d后,有效率、降低HAMD評分及NIHSS評分的療效均高于對照組(單獨(dú)應(yīng)用抗抑郁藥)(P0.05);而不良反應(yīng)發(fā)生率與對照組比較差異無統(tǒng)計(jì)學(xué)意義(P0.05)。養(yǎng)血清腦顆粒單獨(dú)用藥組的有效率、降低HAMD評分的療效及不良反應(yīng)發(fā)生率與對照組比較差異均無統(tǒng)計(jì)學(xué)意義(均P0.05)。結(jié)論養(yǎng)血清腦顆粒能夠有效改善中風(fēng)后抑郁癥狀,且治療效果與臨床上常用的抗抑郁藥基本相當(dāng),并具有良好的安全性。但還需要設(shè)計(jì)上更嚴(yán)謹(jǐn)?shù)亩嘀行�、大樣本、隨機(jī)對照試驗(yàn)來進(jìn)一步證實(shí)此結(jié)論。
[Abstract]:Objective to evaluate the efficacy and safety of Yangxuannao granule in the treatment of post-apoplectic depression, and to provide evidence-based evidence for clinical drug therapy. Methods CNKI, Chinese biomedical literature database (CBM), Wanfang database and Weipu periodical database (VIP), Pub Med,Cochrane Library database were searched by computer to collect the randomized controlled trial of Yangxuannao granule in the treatment of post-apoplectic depression. The time limit for retrieval is from the construction of the database to April 10, 2016. Two evaluators were appointed to sift through the literature and evaluate the methodological quality of the included research. Then the data were extracted and the Meta analysis was performed by RevMan5.3 software. Results Ten randomized controlled trials were included in this Meta analysis, including 1035 patients. The effective rate of Yangxuannao granule combined with antidepressant in the treatment of post-stroke depression 鈮，

本文編號：2265625